Trial Profile
A Phase 2, Open-label, Multicenter Study of Orally Administered Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Ivosidenib (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- Sponsors Servier
- 15 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 06 Dec 2023 Status changed from not yet recruiting to recruiting.
- 16 Oct 2023 New trial record